[Efficacy of Saccharomyces boulardii CNCM I-745 probiotic drug in the prevention and treatment of diarrhea in hospitalized patients with new coronavirus infection COVID-19].
Igor MaevDmitrii N AndreevFilipp S SokolovAleksey K FomenkoM K DevkotaN G AndreevA V ZaborovskyPublished in: Terapevticheskii arkhiv (2022)
CNCM I-745 probiotic drug into the standard treatment regimen of patients with new coronavirus infection COVID-19 receiving antibiotic therapy helps reduce the incidence of diarrhea and its severity during hospitalization, as well as the duration of hospital stay.